|Antisense Therapeutics Ltd.|
6 - 8 Wallace Avenue
Australia - Map
Phone: 61 3 9827 8999
Fax: 61 3 9827 1166
Antisense Therapeutics Limited develops and commercializes novel antisense therapeutics in Australia. The companys product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor to treat prostate cancer. Its product pipeline also includes ATL1103, a second generation antisense drug to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action. Antisense Therapeutics Limited is based in Toorak, Australia.
|Mr. Mark Diamond BSc, MBA, MAICD,
Chief Exec. Officer, Managing Director and Director
|Mr. Phillip Allen Hains CA, MBA,
Chief Financial Officer and Company Sec.
|Dr. George Tachas ,
Director of Drug Discovery & Patents
|Mr. Frank Anastasopoulos ,
| Susan Turner ,
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|